BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 20398872)

  • 21. Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes.
    Han Y; Jing Q; Xu B; Yang L; Liu H; Shang X; Jiang T; Li Z; Zhang H; Li H; Qiu J; Liu Y; Li Y; Chen X; Gao R;
    JACC Cardiovasc Interv; 2009 Apr; 2(4):303-9. PubMed ID: 19463441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two-year follow-up of the Genous™ endothelial progenitor cell capturing stent versus the Taxus Liberté stent in patients with de novo coronary artery lesions with a high-risk of restenosis: a randomized, single-center, pilot study.
    Beijk MA; Klomp M; van Geloven N; Koch KT; Henriques JP; Baan J; Vis MM; Tijssen JG; Piek JJ; de Winter RJ
    Catheter Cardiovasc Interv; 2011 Aug; 78(2):189-95. PubMed ID: 21542109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
    Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective, multicenter, randomized trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-stent restenosis: results from the PEPCAD China ISR trial.
    Xu B; Gao R; Wang J; Yang Y; Chen S; Liu B; Chen F; Li Z; Han Y; Fu G; Zhao Y; Ge J;
    JACC Cardiovasc Interv; 2014 Feb; 7(2):204-211. PubMed ID: 24556098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial.
    Claessen BE; Beijk MA; Legrand V; Ruzyllo W; Manari A; Varenne O; Suttorp MJ; Tijssen JG; Miquel-Hebert K; Veldhof S; Henriques JP; Serruys PW; Piek JJ
    Circ Cardiovasc Interv; 2009 Aug; 2(4):339-47. PubMed ID: 20031737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, controlled, multicenter trial to evaluate the safety and efficacy of zotarolimus- versus paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries The ZoMaxx I trial.
    Chevalier B; Di Mario C; Neumann FJ; Ribichini F; Urban P; Popma JJ; Fitzgerald PJ; Cutlip DE; Williams DO; Ormiston J; Grube E; Whitbourn R; Schwartz LB;
    JACC Cardiovasc Interv; 2008 Oct; 1(5):524-32. PubMed ID: 19463354
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Five-year clinical follow-up of a randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus (LIPSIA Yukon trial).
    Stiermaier T; Heinz A; Schloma D; Kleinertz K; Dänschel W; Erbs S; Linke A; Boudriot E; Lauer B; Schuler G; Thiele H; Desch S
    Catheter Cardiovasc Interv; 2014 Feb; 83(3):418-24. PubMed ID: 23873579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trial.
    Lansky AJ; Ng VG; Mutlu H; Cristea E; Guiran JB; Midei M; Newman W; Sanz M; Sood P; Doostzadeh J; Su X; White R; Cao S; Sudhir K; Stone GW
    Catheter Cardiovasc Interv; 2009 Nov; 74(5):719-27. PubMed ID: 19530147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical outcomes between different stent designs with the same polymer and drug: comparison between the Taxus Express and Taxus Liberte stents.
    Son JW; Kim U; Park JS; Kim YJ; Jang JS; Yang TH; Kim DS; Kim DK; Seol SH; Kim DI; Nam CW; Hur SH; Kim KB
    Korean J Intern Med; 2013 Jan; 28(1):72-80. PubMed ID: 23345999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term safety and efficacy of paclitaxel-eluting stents final 5-year analysis from the TAXUS Clinical Trial Program.
    Stone GW; Ellis SG; Colombo A; Grube E; Popma JJ; Uchida T; Bleuit JS; Dawkins KD; Russell ME
    JACC Cardiovasc Interv; 2011 May; 4(5):530-42. PubMed ID: 21596326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-speed rotational atherectomy before paclitaxel-eluting stent implantation in complex calcified coronary lesions: the randomized ROTAXUS (Rotational Atherectomy Prior to Taxus Stent Treatment for Complex Native Coronary Artery Disease) trial.
    Abdel-Wahab M; Richardt G; Joachim Büttner H; Toelg R; Geist V; Meinertz T; Schofer J; King L; Neumann FJ; Khattab AA
    JACC Cardiovasc Interv; 2013 Jan; 6(1):10-9. PubMed ID: 23266232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of paclitaxel drug-eluting balloon and paclitaxel-eluting stent in small coronary vessels in diabetic and nondiabetic patients - results from the BELLO (balloon elution and late loss optimization) trial.
    Giannini F; Latib A; Jabbour RJ; Costopoulos C; Chieffo A; Carlino M; Montorfano M; Menozzi A; Castriota F; Micari A; Cremonesi A; De Felice F; Marchese A; Tespili M; Presbitero P; Sgueglia GA; Buffoli F; Tamburino C; Varbella F; Colombo A
    Cardiovasc Revasc Med; 2017; 18(1):4-9. PubMed ID: 28011243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent.
    Kirtane AJ; Leon MB; Ball MW; Bajwa HS; Sketch MH; Coleman PS; Stoler RC; Papadakos S; Cutlip DE; Mauri L; Kandzari DE;
    JACC Cardiovasc Interv; 2013 Apr; 6(4):325-33. PubMed ID: 23523453
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-Term Outcomes After Treatment With a Paclitaxel-Coated Balloon Versus Balloon Angioplasty: Insights From the PEPCAD-DES Study (Treatment of Drug-eluting Stent [DES] In-Stent Restenosis With SeQuent Please Paclitaxel-Coated Percutaneous Transluminal Coronary Angioplasty [PTCA] Catheter).
    Rittger H; Waliszewski M; Brachmann J; Hohenforst-Schmidt W; Ohlow M; Brugger A; Thiele H; Birkemeyer R; Kurowski V; Schlundt C; Zimmermann S; Lonke S; von Cranach M; Markovic S; Daniel WG; Achenbach S; Wöhrle J
    JACC Cardiovasc Interv; 2015 Nov; 8(13):1695-700. PubMed ID: 26476609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Paclitaxel-coated balloon with bare-metal stenting in patients with chronic total occlusions in native coronary arteries.
    Wöhrle J; Werner GS
    Catheter Cardiovasc Interv; 2013 Apr; 81(5):793-9. PubMed ID: 22511572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial.
    Xu B; Yang Y; Yuan Z; Du Z; Wong SC; Généreux P; Lu S;
    JACC Cardiovasc Interv; 2013 Jul; 6(7):664-70. PubMed ID: 23523240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of a drug-eluting balloon first and then bare metal stent with a drug-eluting stent for treatment of de novo lesions: study protocol of a randomized controlled trial.
    Park SD; Yoon CH; Oh IY; Suh JW; Cho YS; Youn TJ; Choi DJ; Chae IH
    Trials; 2013 Feb; 14():38. PubMed ID: 23394404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis: the three-year results of the PEPCAD II ISR study.
    Unverdorben M; Vallbracht C; Cremers B; Heuer H; Hengstenberg C; Maikowski C; Werner GS; Antoni D; Kleber FX; Bocksch W; Leschke M; Ackermann H; Boxberger M; Speck U; Degenhardt R; Scheller B
    EuroIntervention; 2015 Dec; 11(8):926-34. PubMed ID: 25169589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Twelve-month results of a paclitaxel releasing balloon in patients presenting with in-stent restenosis First-in-Man (PEPPER) trial.
    Hehrlein C; Dietz U; Kubica J; Jørgensen E; Hoffmann E; Naber C; Lesiak M; Schneider H; Wiemer M; Tölg R; Richardt G
    Cardiovasc Revasc Med; 2012; 13(5):260-4. PubMed ID: 22867706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.